WO2006093211A1 - 抗ウイルス剤 - Google Patents
抗ウイルス剤 Download PDFInfo
- Publication number
- WO2006093211A1 WO2006093211A1 PCT/JP2006/303937 JP2006303937W WO2006093211A1 WO 2006093211 A1 WO2006093211 A1 WO 2006093211A1 JP 2006303937 W JP2006303937 W JP 2006303937W WO 2006093211 A1 WO2006093211 A1 WO 2006093211A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hepatitis
- virus
- antiviral
- hgf
- power
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to an antiviral agent.
- HCV Hepatitis C virus type C
- HCV was only established in infectious humans and chimpanzees !, and because there was no appropriate in vitro infection / replication system in vitro, the development of drugs for hepatitis C was delayed.
- the power of various medicines used for treatment The only effective interferon (hereinafter sometimes abbreviated as “IFN”) and ribavirin are effective in improving viremia.
- IFN interferon
- Ribavirin alone is ineffective against HCV and is only effective in combination with IFN.
- the response rate is 30% with IFN alone and 50% with both drugs.
- patients with high HCV-lb type (gene type) and viral load in Japan are extremely unlikely to be cured. Under such circumstances, development of an effective drug for chronic hepatitis C 'cirrhosis-hepatoma is desired.
- liver protectants may be administered to chronic hepatitis including hepatitis C in order to suppress the progression of hepatocyte necrosis.
- hepatoprotective drugs include strong neominophagen C / adelabin No. 9 'Tathion' as an injection, glycyrone 'thiola' urso 'prohepar', and Shosaikoto. These improve symptomatic liver function tests (leakage enzymes, etc.) through the stabilization of liver cell membranes, etc., and do not eliminate the causative virus. Thus improving viremia No medicinal effects can be expected.
- HCV-subgenomic replicon is an HCV replication model containing RNA in cells (Fig. 3).
- HCV-IRES internal ribosome entry site
- EMCV-IRES downstream neomycin metagene
- EMCV-IRES downstream HCV pseudo-RNA with HCV non-structural gene sequence were transferred to human hepatoma cell line Huh7 cells. Select in the presence of G418.
- replicon RNA replicates autonomously using HCV-derived polymerases, proteases, etc., and can serve as an HCV replication model.
- Non-patent Document 2 This system is widely used for screening anti-HCV agents, and HCV protease inhibitor BILN-2061, which inhibits replication of replicon RNA in this system, has also been shown to improve viremia in patients with hepatitis C. The validity of the system is recognized (Non-patent Document 2).
- HGF hepatocyte growth factor
- HGF has a hepatocyte proliferation-promoting effect, for hepatocellular necrosis production, liver function promoting action, fulminant hepatitis, liver failure, acute indications such as liver transplantation, chronic hepatitis
- liver function promoting action fulminant hepatitis
- liver failure acute indications such as liver transplantation
- chronic hepatitis Both aspects of chronic indications such as cirrhosis have been devised and their pharmaceutical applications are expected (Patent Document 1).
- the HGF itself has the ability to eliminate the hepatitis virus directly.
- Patent Document 1 Japanese Patent Laid-Open No. 3-72883
- Non-Patent Document 1 SCIENCE 285, No. 5424, 110-113 (1999)
- Non-Patent Document 2 Nature 426, No.6963, 186-189 (2003)
- Non-Patent Document 3 Biochem. Biophys. Res. Commun., 163, 967 (1989)
- Non-Patent Document 4 Science, 251,802-804 (1991)
- Non-Patent Document 5 Oncogene, 6, 501-504 (1991)
- Non-Patent Document 6 Experimental Medicine 10, 144-153 (1992)
- Non-Patent Document 7 Arteriosclerosis 23, 683-688 (1996)
- An object of the present invention is to provide a new antiviral agent.
- HCV replication suppression occurs when HGF alone is administered, and the combined use of HGF and an antiviral agent typified by IFN, The present inventors have found that the antiviral agent can suppress the inhibition of HCV replication and have completed the present invention.
- the gist of the present invention is as follows.
- An antiviral agent comprising an antigen of hepatocyte growth factor (HGF) or HGF receptor.
- HGF hepatocyte growth factor
- a pharmaceutical preparation characterized by using HGF or an HGF receptor antigen and one or more antiviral agents simultaneously or separately.
- antiviral agent is one or more selected from HCV protease inhibitor, HCV polymerase inhibitor and HCV helicase inhibitor ability.
- antiviral agent is one or two selected from interferon (IFN) and ribavirin power.
- the antiviral agent is one or more HCV protease inhibitor, HCV polymerase inhibitor and HCV helicase inhibitor power selected (11) or prevention or Z or treatment described in (12) Method.
- a method for improving viremia characterized by using HGF or an HGF receptor antigen and one or more antiviral agents simultaneously or separately.
- a novel antiviral agent can be provided.
- FIG. 1 is a diagram showing the HCV-replicon replication inhibitory effect of IFN and Z or HGF in HCV-replicon cells at various concentrations.
- the horizontal axis shows IFN concentration (IUZml), and the vertical axis shows rep licon replication (arbitrary unit of quantitative PCR).
- the difference in the amount of HGF added at each IFN concentration is shown in three bar graphs. The standard deviation of each sample is indicated by a bar.
- FIG. 2 is a diagram showing the effect on cell proliferation under the same experimental conditions as in FIG.
- the horizontal axis represents the IFN concentration (IUZml), and the vertical axis represents the amount of cell proliferation (absorbance at OD 490 nm).
- the difference in the amount of HGF added at each IFN concentration is shown in three bar graphs with different colors. The standard deviation of each sample is shown as a bar.
- FIG. 3 A schematic diagram of the structure of HCV subgenomic replicon is shown.
- HGF in the present invention is a known substance and is a substance described in Patent Document 1 described above.
- HGF itself binds to its receptor and exerts its action
- Non-Patent Document 4 Non-Patent Document 4
- the effect obtained by using HGF in the present invention is due to the agonist acting on the HGF receptor.
- the same effect can be obtained. Therefore, in the present invention, the same effect can be expected by using an HGF derivative, a partial peptide, an HGF-like low molecular weight compound, an anti-HGF receptor agonist antibody, etc. having the same action as HGF, instead of HGF.
- HGF derivatives include those described in Nature. 342,440-443 (1989).
- Examples of the anti-HGF receptor antibody include antibodies described in J Cell Sci. Ill, 237-247 (1998).
- partial peptide examples include partial peptides derived from HGF described in FEBS Lett. Vol. 22,1-6, (1997) and having an agonistic activity. However, if the substance has an agonistic effect on the HGF receptor, However, it is not limited to the above substances. In addition, substances that do not directly act on the HGF receptor but act on known HGF receptor downstream signal transduction and HGF activation, HGF activator inhibitors, etc. are also included in the present invention. Can be included in the HGF receptor's agost.
- a feature of the present invention is that the above-described HGF or HGF receptor agonist can be used as an antiviral agent. In combination with other antiviral agents, it has been found that the inhibition of HCV replication of the antiviral agents is enhanced.
- the antiviral agent used in the present invention there is no particular limitation as long as it is a substance having inhibitory activity in HCV-subgenomic repli con (Non-patent Document 1)!
- the substance that inhibits H and V-subgenomic replicon means that the amount of revlikon RNA contained in each cell when HCV-subgenomic replicon is added is reduced to 50% or less, more preferably 10% or less.
- a drug that can be Examples include BILN206 1 (Non-patent Document 2), but are not particularly limited as long as the drug has the above action.
- one or more selected from HCV protease inhibitor, HCV polymerase inhibitor and HCV helicase inhibitor power may be mentioned.
- inosine monophosphate dehydrogenase (IMPD H) inhibitors represented by ribavirin are also known to have anti-HCV activity in humans when used in combination with interferon (IFN).
- Viral agents can also include IMPDH inhibitors.
- Specific examples include one or two selected from IFN and ribavirin strength.
- the HGF and IFN can be prepared by various methods as long as they are purified to the extent that they can be used as pharmaceuticals.
- primary HGF or IFN-producing cells or cell lines that produce HGF or IFN can be cultured, separated from the culture supernatant, etc., and purified to obtain HGF or IFN.
- Replacement HGF or IFN can be obtained.
- the above host cells are various host cells conventionally used in genetic engineering techniques such as E. coli, yeast, baculovirus (arthropod polyhedrosis virus) insect cells. Vesicles or animal cells can be used, but is not particularly limited thereto
- the transformant introduced with the recombinant vector is cultured in a medium suitable for each.
- the medium contains a carbon source, a nitrogen source, inorganic substances, vitamins, blood serum, and a drug used for screening for resistance necessary for the growth of the transformant.
- Escherichia coli for example, YLB medium (Genetic Engineering, vol. 1, p. 117, Plenum Press) (1979)
- the host is an insect cell or animal cell
- Ham-12 medium MEM medium, DMEM medium, RPMI1640 medium (manufactured by SIGMA) containing 20% or less urine fetal serum Can do.
- the culture temperature, CO concentration, and culture time depend on the host and recombinant vector.
- the method of recovering the introduced body cultured as described above is, for example, a method in which when the host is a cell, the culture is separated by centrifugation or the like and then recovered as a cell body or a culture supernatant. Etc. are used. Examples of a method for extracting the recovered recombinant protein of cell physical strength include a commonly used method known per se.
- HGF or IFN can also be prepared by a known cell-free protein synthesis system or the like.
- cell extracts used in the cell-free protein synthesis system include microorganisms such as Escherichia coli, plant seed germs, cell extracts such as rabbit reticulocytes, and the like. These can be commercially available, or are known per se, specifically Otsuki Yasu! 3 ⁇ 4In accordance with the method described in Nada Idei, Pratt, JM et al., Transcription and Translation, Hames, BD & Higgins, SJ, et.al., pl79-209, IRL Press, Oxford (1984) It can be prepared.
- IFNs that are listed as reagents and pharmaceuticals can be used. Examples include IFN-a, IFN-j8, IFN- ⁇ , and consensus IFN. Polyethylene glycol A modified IFN such as Louis moth can also be used. It is not particularly limited to the above-mentioned subtypes and modified compounds as long as an antiviral effect is recognized.
- amino acids in the amino acid sequence of HGF or IFN used in the present invention are substituted, deleted and Z or added as long as they have substantially the same action as the natural type.
- sugar chains may be substituted, deleted, and / or added.
- nucleic acid that hybridizes with the nucleic acid shown in Patent Document 1 by a conventional Northern blotting method and a protein derived therefrom can also be included in the HGF referred to in the present invention.
- Northern blotting is specifically a force that can be carried out by the method described in Chapter 10 Northern Hybridization of Bio-Experimental Illustrated 2 Gene Analysis Basics (Shujunsha). It can be carried out using a general Northern blotting protocol, and is not limited to the methods described in the above references and the methods exemplified below.
- RNA is extracted from a gel subjected to agarose electrophoresis of cell force extracted according to a conventional method, and RNA is hybridized to a membrane obtained by transferring the RNA to a nitrocellulose or nylon membrane using a probe derived from the nucleic acid described in Patent Document 1.
- the membrane is combined with a nucleic acid probe prepared using the nucleic acid shown in Patent Document 1, and the membrane is mixed with a hybridization buffer 5 X SSPE (750 mM NaCl, 43.3 mM NaPO (p
- the force exemplified above as a hybridizing buffer No particular limitation as long as it is a hybridizing buffer that can be used for general Northern blotting.
- the nucleic acid probe can be RI-labeled, or labeled with a chemical such as DIG, biotin, or fluorescein, or labeled with an enzyme such as alkaline phosphatase or peroxidase according to a conventional method.
- Hybridized nucleic acid probes can be detected by direct exposure to X-ray film in the case of RI labeling, and in the case of chemical labeling, by adding an antibody to the enzyme-labeled substance and then incubating with a luminescent substance on the X-ray film. If the exposure method is enzyme-labeled, X-ray film is exposed by incubating membrane with a luminescent substance. Forces that can be performed by the method The method is not particularly limited as long as it is a method capable of detecting hybridization between a nucleic acid probe and RNA.
- hybridization it is also possible to perform hybridization by reducing the salt concentration of the hybridization buffer or increasing the formamide concentration. Specifically, hybridization can be carried out in the same manner using a buffer having a Na concentration of 1-50 mM to 800 mM. It is also possible to perform hybridization at a formamide concentration of 50-70%. Within these salt and formamide concentrations, the hybridized nucleic acid and protein derived from it at 42-65 ° C. Is included in the claims of this patent.
- ribavirin those listed above as pharmaceuticals can be used. Specifically, what is sold as Lebetol (registered trademark) by Shielding Prou can be used. As a dose, it is desirable that the daily dose is 50 to 5000 mg, preferably 600 to 800 mg, which is taken orally in two divided doses a day. However, the dose is not particularly limited as long as antiviral activity is observed. In addition, a product sold as a Merck reagent (product number 555580) can also be used.
- the present invention provides a method for preventing and preventing a disease caused by hepatitis C virus, characterized by using HGF or an HGF receptor antigen and an antiviral agent simultaneously or separately.
- the diseases caused by hepatitis c virus include, for example, acute hepatitis, chronic hepatitis, cirrhosis and liver cancer.
- the present invention also provides a method for improving viremia by using a combination of an HGF or HGF receptor antigen and an antiviral agent.
- HGF or HGF receptor antigen alone or in combination with other antiviral agents such as IFN, and further with appropriate additive for pharmaceutical preparation can be prepared and administered as a pharmaceutical composition in the form.
- the administration form of such a pharmaceutical composition is not particularly limited as long as it is generally used, and an ampoule for injection, a freeze-dried powder for injection, and the like can be used.
- Preparation into various pharmaceutical forms can be performed according to a conventional technique using known pharmaceutical additives available to those skilled in the art, such as diluents and additives.
- the freeze-dried powder for injection is purified HGF and Z or other anti-virus.
- An effective amount of a Ruth agent can be dissolved in a diluent, and an excipient, a stabilizer, a preservative, an analgesic agent, a pH adjuster, etc. can be added as necessary, and the product can be produced by a conventional method.
- ampules for injection are prepared by dissolving an effective amount of the above HGF or other antiviral agent in a diluent, and if necessary, a solubilizer, buffer, isotonic agent, stabilizer, preservative, painless. It can be prepared by sterilizing by usual heat sterilization, aseptic filtration, etc. after adding an additive such as an agent and a pH adjuster.
- the HGF or HGF receptor antigen and other antiviral agent are used simultaneously refers to the case where these are used in combination and the case where they are used as a mixture. In both senses.
- a solid form such as a tablet, granule, capsule or powder, or a liquid, suspension, syrup
- a pharmaceutical preparation formulated into a dosage form suitable for oral administration, inhalation administration or external use in a liquid form such as an emulsion or a lemonade agent.
- adjuvants, stabilizers, wetting agents, and other commonly used additives may be added to the above preparation.
- the dosage of the above various pharmaceutical preparations varies depending on the route of administration, type of illness, patient symptom, body weight or age, etc., and also varies depending on the type of drug to be applied.
- a daily dose of lmg to 200mg or more can be administered per patient.
- an average dose of HGF contained as an active ingredient in the range of 5 mg to about LOO mg for the prevention and Z or treatment of liver damage.
- IFN In the case of IFN, it has already been promoted with the indication of ⁇ improvement of viremia in chronic active hepatitis C ''.
- Canferon A IFN alpha-2a gene recombinant product, Takeda Pharmaceutical
- Three to nine million international units are administered.
- the HGF gene and the Z or IFN gene are used as a gene therapy for the prevention and Z or treatment of liver damage caused by hepatitis C virus, and the HGF gene and It can be used as a cell therapy that introduces Z or IFN genes and transplants the cells into tissues.
- the HGF gene and the Z or IFN gene of the present invention with a lipofusion reagent and administering it to a living body, local HGF and Z or IFN can be used to prevent liver damage caused by hepatitis C virus and to prevent Z. Or it can be maintained at the concentration required for treatment.
- HGF and Z or IFN of the present invention depends on the severity of the disease state and the responsiveness of the living body, but the prevention and prevention of Z or treatment are confirmed, or the reduction of the disease state is achieved. Appropriate dose, administration method, and frequency may be used for the period up to.
- HCV-replicon cell clone # 5-15 which is the human hepatoma cell line Huh7, was used (purchased from ReBLikon GmbH). # 5-15 was suspended in Dulbecco's Eagle MEM medium containing 2% urine fetal serum and seeded on a 96-well plate at 1.5 X loVlOO ⁇ lZwell. Without seeding the cells as a blank, a well containing only the medium was prepared (Day 0). After overnight culture in a 37 ° C wet incubator under 5% C02 gas, human recombinant IFN a (BIOMEDICAL LABORATORIES, Cat.No. 11105-1, lot No.
- HCV-replicon RNA was quantified by quantitative PCR (Polymerase chain reaction).
- ABI PRISM7900 Applied Biosystems
- quantification was performed according to the method of Takeuchi et al. (Takeuchi, T. et al. Gastroenterology Vol. 116, 636-642 (1999)).
- RNA for the standard curve used for quantitative PCR was T7 RiboMAX using a vector in which the gene for HCV MKC-1A strain (Genbank accession No. D45172) was connected downstream of the T7 promoter. Prepared by in vitro transcription using Express Large Scale RNA production System (Promega), and it is confirmed that linearity can be obtained from 10 2 to 10 8 in the above quantitative PCR.
- HGF HGF alone inhibited HCV replicon replication.
- HGF acted synergistically to suppress HCV-replicon replication (Fig. 1).
- Example 1 The following experiment was conducted for the purpose of ascertaining whether or not the HCV-replicon replication amount reducing ability observed in Example 1 was caused by the decrease in the cell number itself.
- Each sample was prepared with 3 triples (triplicate) (Dayl).
- the number of cells was quantified using CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Pot Mega, Lot. # 171755), a type of cell proliferation assay.
- the operation was performed according to the operation manual of Atsy Kit. That is, 100 1 of the culture supernatant was removed from each well, and One Solution Reagent 201 in the Atsey kit was added to each well. The plate is then set to 37 ° C. After culturing for 1 hour in a wet incubator containing 5% C02, the absorbance at 490 nm was measured using a 96 well plate reader.
- HGF hepatocyte growth factor
- results we have shown for the first time provide a novel use of HGF as a preventive and Z or therapeutic agent for diseases caused by HCV.
- HGF acted synergistically to suppress HCV-replicon replication.
- IFN and HGF have different mechanisms for virus replication because IFN-dependent viral replication suppression is synergistically enhanced even at a concentration (10 ng / ml) at which replication suppression is hardly observed with HGF alone. It is suggested to suppress the Conventional HCV antiviral agents such as IFN do not have sufficient virus elimination ability even in extremely high doses in clinical practice. The results we have shown suggest that HGF may enhance HCV viremia improvement by a mechanism different from conventional antiviral agents. HCV is a combination or mixed preparation of HGF and existing antiviral agents. It provides promising and new treatments for diseases caused by this.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/885,418 US20090028820A1 (en) | 2005-03-02 | 2006-03-02 | Antiviral Agent |
EP06715046A EP1867339A4 (en) | 2005-03-02 | 2006-03-02 | ANTIVIRAL MEDIUM |
JP2007505996A JPWO2006093211A1 (ja) | 2005-03-02 | 2006-03-02 | 抗ウイルス剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005057699 | 2005-03-02 | ||
JP2005-057699 | 2005-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006093211A1 true WO2006093211A1 (ja) | 2006-09-08 |
Family
ID=36941240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/303937 WO2006093211A1 (ja) | 2005-03-02 | 2006-03-02 | 抗ウイルス剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090028820A1 (ja) |
EP (1) | EP1867339A4 (ja) |
JP (1) | JPWO2006093211A1 (ja) |
CN (1) | CN101151046A (ja) |
WO (1) | WO2006093211A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8464182B2 (en) * | 2009-06-07 | 2013-06-11 | Apple Inc. | Device, method, and graphical user interface for providing maps, directions, and location-based information |
WO2020081634A2 (en) * | 2018-10-16 | 2020-04-23 | George Mason Research Foundation, Inc. | Compositions and methods for modulation of extracellular vesicle release and treatment of neurological disorders |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2784455B2 (ja) * | 1990-05-09 | 1998-08-06 | 敏一 中村 | 肝硬変治療剤 |
US6566098B1 (en) * | 1990-09-14 | 2003-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | DNA encoding truncated hepatocyte growth factor variants |
CA2144081C (en) * | 1992-09-16 | 2004-11-30 | Filip Roos | Protection against liver damage by hgf |
AU729029B2 (en) * | 1996-07-03 | 2001-01-25 | Genentech Inc. | Hepatocyte growth factor receptor agonists and uses thereof |
JP4463885B2 (ja) * | 1996-12-05 | 2010-05-19 | 敏一 中村 | 劇症肝炎疾患治療剤 |
JP2004269538A (ja) * | 2004-03-31 | 2004-09-30 | Toshiichi Nakamura | 成熟組換肝実質細胞増殖因子 |
-
2006
- 2006-03-02 CN CNA2006800105079A patent/CN101151046A/zh active Pending
- 2006-03-02 WO PCT/JP2006/303937 patent/WO2006093211A1/ja active Application Filing
- 2006-03-02 JP JP2007505996A patent/JPWO2006093211A1/ja not_active Withdrawn
- 2006-03-02 EP EP06715046A patent/EP1867339A4/en not_active Withdrawn
- 2006-03-02 US US11/885,418 patent/US20090028820A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
RAMPINO T. ET AL.: "Hemodialysis prevent liver disease caused by hepatitis C virus: Role of hepatocyte growth factor", KIDNEY INTERNATIONAL, vol. 56, 1999, pages 2286 - 2291, XP003004005 * |
See also references of EP1867339A4 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006093211A1 (ja) | 2008-08-07 |
US20090028820A1 (en) | 2009-01-29 |
EP1867339A1 (en) | 2007-12-19 |
CN101151046A (zh) | 2008-03-26 |
EP1867339A4 (en) | 2010-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101755058B1 (ko) | 특정 hcv ns5a 억제제 및 hcv ns3 프로테아제 억제제의 조합물 | |
US20070224167A1 (en) | Novel HCV inhibitor combinations and methods | |
EA029145B1 (ru) | Ингибиторы hcv сериновой протеазы, полученные из макроциклического пролина | |
TW201300108A (zh) | C型肝炎病毒(hcv)ns3-ns4a蛋白酶抑制劑 | |
JPH0717510B2 (ja) | Aidsの予防及び治療剤 | |
WO2008024843A2 (en) | Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein | |
US20130109647A1 (en) | Methods and compositions for treating hepatitis c virus | |
CA2853495A1 (en) | Methods and compositions for treating hepatitis c virus | |
US9511070B2 (en) | Heterocyclyl carboxamides for treating viral diseases | |
WO2006093211A1 (ja) | 抗ウイルス剤 | |
EP3912627B1 (en) | Methods for the treatment of coronavirus infections | |
EP2542240B1 (en) | Compositions and methods for treating viral diseases | |
US20230270826A1 (en) | Antiviral use of liraglutide and gefitinib | |
US11364256B2 (en) | Viral inhibition | |
MX2008016166A (es) | Agente profilactico o terapeutico para enfermedad viral. | |
KR20220023204A (ko) | 섬유아세포 성장인자 11을 유효성분으로 포함하는 항바이러스 조성물 | |
US10016377B2 (en) | Treatment of hepatitis C using histone deacetylase inhibitors | |
US10071062B2 (en) | Methods for the treatment of hepatitis C | |
JP2007015926A (ja) | C型肝炎治療剤 | |
JP6656670B2 (ja) | 抗hcv活性を有する薬剤 | |
KR101475056B1 (ko) | 설폰아미드계 화합물을 유효성분으로 포함하는 c형 간염의 예방 또는 치료용 약학적 조성물 | |
KR20120071376A (ko) | 설폰아미드계 화합물을 유효성분으로 포함하는 c형 간염의 예방 또는 치료용 약학적 조성물 | |
JP2012031098A (ja) | C型肝炎ウイルス感染阻害剤及びそれを含有する医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680010507.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007505996 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006715046 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11885418 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2006715046 Country of ref document: EP |